Kcentra superior to plasma in surgery-CSL Behring

New data from a Phase IIIb study shows Kcentra (Prothrombin Complex Concentrate), from CSL Behring, was superior to plasma, the current standard of care in the US in adult patients taking vitamin K antagonist therapy (eg warfarin) who required warfarin reversal prior to an urgent surgery or invasive procedure. It showed that Kcentra was superior to plasma in achieving effective hemostasis (89.7% of patients on Kcentra versus 75.3% of patients treated with plasma) and early International Normalized Ratio reduction to less than or equal to 1.3 at 30 minutes after the end of infusion (55.2% of patients treated with Kcentra versus 9.9% of patients treated with plasma).

The study also found that Kcentra was well-tolerated and that the incidences of adverse events, serious adverse events, thromboembolic events, and deaths were similar between treatments. Results were presented at the 55th Annual Meeting of the American Society of Hematology.